[go: up one dir, main page]

CL2019001660A1 - (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas. - Google Patents

(aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.

Info

Publication number
CL2019001660A1
CL2019001660A1 CL2019001660A CL2019001660A CL2019001660A1 CL 2019001660 A1 CL2019001660 A1 CL 2019001660A1 CL 2019001660 A CL2019001660 A CL 2019001660A CL 2019001660 A CL2019001660 A CL 2019001660A CL 2019001660 A1 CL2019001660 A1 CL 2019001660A1
Authority
CL
Chile
Prior art keywords
benzothiophen
sulfonamides
benzofuran
aza
indole
Prior art date
Application number
CL2019001660A
Other languages
English (en)
Inventor
Christa E Mueller
Cécile Pegurier
Michael Louis Robert Deligny
Ali El-Tayeb
Joerg Hockemeyer
Marie Ledecq
Joël Mercier
Laurent Provins
Nader M Boshta
Sanjay Bhattarai
Vigneshwaran Namasivayam
Mario Funke
Lukas Schwach
Sabrina Gollos
LAUFENBERG Daniel VON
Anaïs Barré
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CL2019001660A1 publication Critical patent/CL2019001660A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE SULFONAMIDA CON PROPIEDADES MODULADORAS DE GPR17, QUE SON ÚTILES PARA TRATAR O PREVENIR UNA VARIEDAD DE ENFERMEDADES DEL SNC Y OTRAS ENFERMEDADES, EN PARTICULAR PARA PREVENIR Y TRATAR ENFERMEDADES O TRASTORNOS MIELINIZANTES.
CL2019001660A 2016-12-28 2019-06-17 (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas. CL2019001660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16207137 2016-12-28

Publications (1)

Publication Number Publication Date
CL2019001660A1 true CL2019001660A1 (es) 2019-10-25

Family

ID=57614285

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001660A CL2019001660A1 (es) 2016-12-28 2019-06-17 (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.

Country Status (26)

Country Link
US (4) US11345662B2 (es)
EP (1) EP3562820A1 (es)
JP (2) JP6946436B2 (es)
KR (1) KR102537100B1 (es)
CN (3) CN116036078B (es)
AR (1) AR110592A1 (es)
AU (2) AU2017387695B2 (es)
CA (1) CA3045244A1 (es)
CL (1) CL2019001660A1 (es)
CO (1) CO2019007829A2 (es)
CR (1) CR20190287A (es)
EA (1) EA201991553A1 (es)
EC (1) ECSP19044183A (es)
IL (2) IL295047B2 (es)
MX (1) MX2019006190A (es)
MY (1) MY199872A (es)
NZ (1) NZ753651A (es)
PE (1) PE20191475A1 (es)
PH (1) PH12019501095A1 (es)
RU (1) RU2767904C2 (es)
TN (1) TN2019000165A1 (es)
TW (1) TWI754702B (es)
UA (1) UA127890C2 (es)
UY (1) UY37554A (es)
WO (1) WO2018122232A1 (es)
ZA (1) ZA201903466B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939319B2 (en) 2018-06-19 2024-03-26 Ucb Pharma Gmbh Pyridinyl and pyrazinyl-(asa)indolsulfonamides

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
WO2019204813A1 (en) * 2018-04-20 2019-10-24 Virginia Tech Intellectual Properties, Inc. Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
JP7535500B2 (ja) * 2018-09-03 2024-08-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
CN110128422B (zh) * 2019-01-04 2022-03-18 金凯(辽宁)生命科技股份有限公司 5-甲氧基-7-氮杂吲哚的合成方法
US20220388957A1 (en) * 2019-01-17 2022-12-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
GB201903671D0 (en) 2019-03-18 2019-05-01 Univ Edinburgh Small molecule photosensitizers for photodynamic therapy
US12358875B2 (en) * 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
CA3181413A1 (en) * 2020-05-01 2021-11-04 The Children's Medical Center Corporation Compositions and methods of promoting myelination
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
CN112266328B (zh) * 2020-12-09 2023-11-03 郑州萃智医药科技有限公司 3-氟-4-硝基苯甲醛的合成路线及制备方法
MA63458B1 (fr) 2021-02-26 2026-01-30 F. Hoffmann-La Roche Ag Nouveaux dérivés de sulfonamide pyrimidin-2-yl
US20240299385A1 (en) * 2021-06-04 2024-09-12 Rewind Therapeutics Nv 3-pyrrolylsulfonamide compounds as gpr17 antagonists
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
CN114276319B (zh) * 2022-01-06 2023-11-03 滁州学院 一种劳拉替尼中间体的合成方法
CN114315741B (zh) * 2022-01-19 2023-09-12 贵州医科大学 一种硫代化合物及其制备方法与应用
CN119546608A (zh) * 2022-07-20 2025-02-28 豪夫迈·罗氏有限公司 新颖咪唑并吡啶和吡唑并吡啶磺酰胺衍生物
EP4558483A1 (en) 2022-07-20 2025-05-28 F. Hoffmann-La Roche AG Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
WO2024017863A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel pyrimidinyl and triazinyl sulfonamide derivatives
US20260027104A1 (en) 2022-07-20 2026-01-29 Hoffmann-La Roche Inc. Novel naphthyl and isoquinoline sulfonamide derivatives
WO2024017855A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
JP2025537876A (ja) * 2022-11-20 2025-11-20 ミロバラン セラピューティクス，インコーポレイテッド Ｇｐｒ１７モジュレーター及びその使用
JP2025539466A (ja) * 2022-12-02 2025-12-05 リワインド セラピューティクス エン ヴェー 縮合ピロリルスルホンアミド化合物
WO2024153233A1 (en) * 2023-01-19 2024-07-25 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as gpr17 antagonists
CN116947879B (zh) * 2023-07-25 2025-10-31 沈阳药科大学 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用
TW202515863A (zh) * 2023-08-15 2025-04-16 美商百健Ｍａ公司 作為ｇｐｒ１７調節劑之吲哚及吡咯并吡啶衍生物
WO2025195241A1 (zh) * 2024-03-19 2025-09-25 迈巴制药(南京)有限公司 Gpr17受体抑制剂及其用途
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
WO2025243046A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
GB2642355A (en) * 2024-07-05 2026-01-07 Pheno Therapeutics Ltd Polymorphs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
IL144781A0 (en) * 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
WO2002092585A1 (en) * 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SE0102048D0 (sv) * 2001-06-11 2001-06-11 Pharmacia Ab New Compounds
JP4685767B2 (ja) 2004-04-27 2011-05-18 武田薬品工業株式会社 Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20042007A1 (it) 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
DE112008002309A5 (de) 2007-06-25 2010-05-27 Acino Ag Elektrophoretisches transdermales Applikationssystem
BRPI0821915A2 (pt) * 2007-12-26 2015-06-16 Sanofi Aventis Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
GB2491520A (en) 2010-03-11 2012-12-05 Jerry Swinford Method and apparatus for washing downhole tubulars and equipment
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
CN104428288B (zh) * 2012-05-09 2018-03-13 伊泰莲娜多发性硬化症基金会—Imf非营利组织 Gpr17受体调节剂
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
EP2998294A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP2997966A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
WO2016089062A2 (en) * 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
EP3412660B9 (en) * 2016-02-05 2021-04-14 EA Pharma Co., Ltd. Sulfonamide derivative and pharmaceutical composition containing same
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939319B2 (en) 2018-06-19 2024-03-26 Ucb Pharma Gmbh Pyridinyl and pyrazinyl-(asa)indolsulfonamides

Also Published As

Publication number Publication date
IL295047B2 (en) 2024-09-01
MY199872A (en) 2023-11-27
PH12019501095A1 (en) 2019-12-02
ZA201903466B (en) 2020-11-25
IL295047B1 (en) 2024-05-01
IL295047A (en) 2022-09-01
IL267438A (en) 2019-08-29
US20230348384A1 (en) 2023-11-02
CN116283712A (zh) 2023-06-23
TWI754702B (zh) 2022-02-11
CN110121499B (zh) 2022-12-20
JP2020504753A (ja) 2020-02-13
AU2022235580A1 (en) 2022-10-13
EA201991553A1 (ru) 2020-01-09
CN116036078B (zh) 2025-09-02
CR20190287A (es) 2019-08-06
AU2022235580B2 (en) 2024-03-28
AU2017387695B2 (en) 2022-06-23
RU2019123031A3 (es) 2021-03-22
CN110121499A (zh) 2019-08-13
ECSP19044183A (es) 2020-01-31
IL267438B2 (en) 2023-07-01
WO2018122232A1 (en) 2018-07-05
US11820746B2 (en) 2023-11-21
JP2022003051A (ja) 2022-01-11
NZ753651A (en) 2022-10-28
CN116036078A (zh) 2023-05-02
UA127890C2 (uk) 2024-02-07
US20220127227A1 (en) 2022-04-28
UY37554A (es) 2018-07-31
JP6946436B2 (ja) 2021-10-06
KR20190098243A (ko) 2019-08-21
RU2019123031A (ru) 2021-02-01
US12071404B2 (en) 2024-08-27
AR110592A1 (es) 2019-04-10
IL267438B1 (en) 2023-03-01
CN116283712B (zh) 2025-08-19
AU2017387695A1 (en) 2019-06-06
JP7270011B2 (ja) 2023-05-09
RU2767904C2 (ru) 2022-03-22
KR102537100B1 (ko) 2023-05-25
US20220048858A1 (en) 2022-02-17
PE20191475A1 (es) 2019-10-16
TN2019000165A1 (en) 2020-10-05
US20190345104A1 (en) 2019-11-14
EP3562820A1 (en) 2019-11-06
CA3045244A1 (en) 2018-07-05
MX2019006190A (es) 2019-11-18
TW201831448A (zh) 2018-09-01
US11345662B2 (en) 2022-05-31
BR112019012550A2 (pt) 2019-11-12
CO2019007829A2 (es) 2019-07-31

Similar Documents

Publication Publication Date Title
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
CL2019002824A1 (es) Anticuerpos anti-lag3.
MX383652B (es) Moduladores de la vía de estrés integrada.
MX377710B (es) Anticuerpos monoclonales contra bcma.
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112016017644A2 (pt) conjugados de fator vii
CO2020003134A2 (es) Moduladores de la expresión de enac
EA201792492A1 (ru) Aml-антигены и их применение
UA114708U (uk) Тяговий привід електробуса
BR112018003226A2 (pt) implantes
IT201600069689U1 (it) Benda elastica, particolarmente per l’impiego nel trattamento del flebo-linfoedema.
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
BR112017018119A2 (pt) processo para a preparação de triazóis
UA111926C2 (uk) Склад смузі "бадьорість"
TN2014000522A1 (fr) لوح مدرسي بوجهين
UA104340U (uk) Склад смузі "бадьорість"
UA93885U (uk) Засіб у формі песаріїв для лікування гінекологічних захворювань